Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Short term Debt (2020 - 2024)

Syndax Pharmaceuticals (SNDX) has disclosed Short term Debt for 5 consecutive years, with $12.1 million as the latest value for Q4 2024.

  • For Q4 2024, Short term Debt changed N/A year-over-year to $12.1 million; the TTM value through Dec 2024 reached $12.1 million, changed N/A, while the annual FY2024 figure was $12.1 million, N/A changed from the prior year.
  • Short term Debt hit $12.1 million in Q4 2024 for Syndax Pharmaceuticals, up from $7.2 million in the prior quarter.
  • Across five years, Short term Debt topped out at $12.1 million in Q4 2024 and bottomed at $187000.0 in Q4 2021.
  • Average Short term Debt over 4 years is $5.8 million, with a median of $5.8 million recorded in 2021.
  • Year-over-year, Short term Debt plummeted 91.82% in 2021 and then rose 2.59% in 2022.
  • Syndax Pharmaceuticals' Short term Debt stood at $2.3 million in 2020, then tumbled by 91.82% to $187000.0 in 2021, then skyrocketed by 3756.68% to $7.2 million in 2022, then surged by 68.0% to $12.1 million in 2024.
  • According to Business Quant data, Short term Debt over the past three periods came in at $12.1 million, $7.2 million, and $3.6 million for Q4 2024, Q2 2022, and Q1 2022 respectively.